Hemorrhage Clinical Trial
Official title:
Does Ketorolac Increase the Risk of Hematoma After Reduction Mammoplasty? A Case-control Study.
The investigators hope to answer the question, "does ketorolac increase the risk of hematoma after reduction mammoplasty?" using a case-control study. All patients who developed a hematoma post reduction mammoplasty (cases) at our institution, and match these with women who had an uncomplicated reduction mammoplasty (controls), and then compare frequency of ketorolac exposure between these two groups as the primary outcome. If ketorolac increases the risk of hematoma, one should expect cases to have been exposed to ketorolac more frequently than controls. Based on previously existing literature, the investigators hypothesize that cases and controls will not differ in their ketorolac exposure, that is, ketorolac does not increase the risk of hematoma.
The electronic health record databases of St. Joseph's Healthcare Hamilton and Hamilton
Health Sciences will be searched, using the coding system, for all cases of reduction
mammoplasty with post--operative hematoma as a complication. Only hematomas which required
return to the operating room for evacuation will be included (i.e. those treated with
observation or needle aspiration will be excluded).
Cases are defined as patients suffering a hematoma post reduction mammoplasty will be
identified through hospital coding, and matched with controls based on the following
criteria: age, body mass index (BMI), pre-existing hypertension, and institution. Controls
are defined as patients who had uncomplicated reduction mammoplasty, and will be randomly
pulled through retrospective chart review within the same databases, in the same time period
(±5 years).
All patient data will be de--identified, and all devices containing patient information will
remain on hospital grounds, and be encrypted according to our hospital protocols. The
following data will be extracted from patient charts: age, date of surgery, body mass index,
surgeon, anesthetist, volume of breast tissue removed per breast, comorbidities, platelet
count, coagulation profile, ketorolac and opioid use including dose, timing, frequency,
duration, and route of administration of both, time to discharge including length of stay if
overnight, comorbidities (including smoking status), American Society of Anesthesiology
score, and post--operative usage of drains.
Matching of cases and controls will be performed by the primary investigator (JB), and at the
time of matching, the only visible patient information will be the de-identified patient
identification (ID) and the four matching variables (ketorolac exposure was not visible).
The frequency of ketorolac exposure between cases and controls will then be reviewed, and the
odds ratio (OR) of exposure to ketorolac, with 95% confidence intervals will be calculated. A
two by two table will be generated from our data. Since the incidence of hematoma formation
after reduction mammoplasty is very low, the odds ratio will closely approximate the relative
risk. To evaluate the statistical significance of the ORs, a level of significance of 0.05
will be used. Independent samples t-test will be used to compare continuous demographic data,
and Chi-square analysis will be used for ordinal or categorical data between cases and
controls.
Sample size was calculated using the POWER program, described by Dupont and Plummer in 1990.
A sample size of 25 cases matched with 25 controls (total n = 50) was required from the
following data:
- p0 = 0.32 (approximate rate of ketorolac exposure amongst breast reduction patients from
previous literature from Cawthorn et al.)
- α = 0.05 (chance of type I error)
- P = 0.8 (power)
- m = 1 (matching ratio1:1)
- Ψ = 3.6 (estimated risk ratio of developing hematoma post breast reduction if exposed to
ketorolac, Cawthorn et al.)
- Φ = 0.2 (measurable difference)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02815670 -
Reversal Dabigatran Anticoagulant Effect With Idarucizumab
|
Phase 3 | |
Completed |
NCT04588350 -
Clinical Investigation Evaluating a New Autotransfusion Device in Cardiac Surgery
|
N/A | |
Recruiting |
NCT02972385 -
Pharmacogenomics of Warfarin in Hispanics and Latinos
|
||
Completed |
NCT02569606 -
Transfusion and Coagulation Management in Trauma Patients After the Introduction of a Coagulation Algorithm
|
||
Completed |
NCT02554006 -
Predischarge Bundle to Minimize Negative Impact on Quality of Life of Nuisance Bleedings
|
N/A | |
Recruiting |
NCT02446730 -
Efficacy and Safety of BiomatrixTM Stent and 5mg-Maintenance Dose of Prasugrel in Patients With Acute Coronary Syndrome
|
Phase 4 | |
Completed |
NCT01955720 -
Safety, Tolerability, PK and PD of BI 655075 and Establishment of BI 655075 Dose(s) Effective to Reverse Prolongation of Blood Coagulation Time by Dabigatran
|
Phase 1 | |
Completed |
NCT01935427 -
Comparison of Compensatory Reserve Index to Intravascular Volume Change and Stroke Volume
|
N/A | |
Recruiting |
NCT01709786 -
Non-Invasive Hemoglobin Monitoring in Patients With Hemorrhage
|
N/A | |
Completed |
NCT01191554 -
Dose-ranging Study of Tranexamic Acid in Valve Surgery
|
N/A | |
Completed |
NCT01210417 -
Trauma Heart to Arm Time
|
N/A | |
Completed |
NCT01136590 -
Multicenter, Randomized Placebo-controlled Clinical Trial to Evaluate the Effect of Perioperative Use of Tranexamic Acid on Transfusion Requirements and Surgical Bleeding in Major Spine Surgery
|
Phase 4 | |
Completed |
NCT01085006 -
The Effect of Tranexamic Acid on Postpartum Hemorrhage During and After Cesarean Delivery
|
Phase 1/Phase 2 | |
Completed |
NCT00700141 -
Non-Interventional Study About Treatment of Hemorrhages in Thyroid Surgery With TachoSil®
|
N/A | |
Completed |
NCT00375466 -
Tranexamic Acid, Hemorrhage and Transfusions After Combined Aortic Valve Replacement and Coronary Artery Bypass Surgery.
|
N/A | |
Completed |
NCT00147420 -
RCT of Zhi Byed 11 (ZB11) Versus Misoprostol in Tibet
|
N/A | |
Completed |
NCT00479362 -
Anticoagulant Therapy During Pacemaker Implantation
|
Phase 4 | |
Recruiting |
NCT05945680 -
Tranexamic Acid in Breast Esthetic Surgery.
|
Phase 4 | |
Completed |
NCT03273322 -
Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
|
Phase 2/Phase 3 | |
Withdrawn |
NCT05672407 -
The Role of Local Tranexamic Acid on Periorbital Oculoplastic Surgery
|
Phase 4 |